Urgent research is ongoing around the world aiming at finding the most effective Covid-19 vaccine. These products should comply with the same legal requirements of pharmaceutical quality, safety and efficacy as any other medicine. The substances are first tested in laboratories then on human volunteers within the framework of clinical trials. Only drugs with successfully completed phase III clinical trials are suitable to apply for marketing authorisation from the competent – national or regional – drug safety authorities. At this moment, recent developments are reported to having reached the end of phase III clinical trials, and in some cases, conditional marketing authorisation procedures are ongoing and in some cases concluded.
You can read the rest of the article
here